Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR)

Oncology Pharma (OTCMKTS:ONPH) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Oncology Pharma and Larimar Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Pharma	N/A	N/A	N/A
Larimar Therapeutics	N/A	-91.83%	-74.60%

Analyst Ratings

This is a summary of current ratings for Oncology Pharma and Larimar Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Pharma	0	0	0	0	0.00
Larimar Therapeutics	1	0	8	1	2.90

Larimar Therapeutics has a consensus price target of $16.71, indicating a potential upside of 434.00%. Given Larimar Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Oncology Pharma.

Volatility & Risk

Oncology Pharma has a beta of -0.93, indicating that its share price is 193% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Valuation and Earnings

This table compares Oncology Pharma and Larimar Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Pharma	N/A	N/A	N/A	N/A	N/A
Larimar Therapeutics	N/A	N/A	-$80.60 million	($1.93)	-1.62

Institutional and Insider Ownership

91.9% of Larimar Therapeutics shares are owned by institutional investors. 18.0% of Oncology Pharma shares are owned by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Larimar Therapeutics beats Oncology Pharma on 6 of the 9 factors compared between the two stocks.

About Oncology Pharma

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.